Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Bigger Picture

This article was originally published in RPM Report

Executive Summary

Here are the many steps recommended in the Obama Administration’s Prescription Drug Abuse Prevention Plan, the vehicle for launching the final opioid REMS. Each recommendation is tagged to one or more agencies for action.

You may also be interested in...

Market Research with a Twist

As in any other REMS, a key burden on sponsors of long-acting opioids will be tracking the success the program. Here are the metrics FDA asks for in its April 19 REMS.

The Opioid REMS Template

Here is the final version of the Risk Evaluation & Mitigation Strategy FDA is imposing on two dozen sponsors of long-acting opioids. It was included in a letter to the sponsors sent April 19.

Controlling Opioids: REMS Meets Congressional Resistance

The Food & Drug Administration’s work on curbing abuse of long-acting opioids hasn’t lacked for outreach. The three-year long effort to develop a formal Risk Evaluation & Mitigation Strategy to help ensure appropriate use of products like Purdue Pharma’s OxyContin has involved input from two dozen different manufacturers, formal presentations by more than 75 outside stakeholder groups, and literally hundreds of public comments.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts